A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from Circulating Tumor DNA: LiquidLung-O-Cohort 2
about
A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from Circulating Tumor DNA: LiquidLung-O-Cohort 2
description
scientific article published on 07 September 2018
@en
name
A Phase II Trial of Osimertini ...... mor DNA: LiquidLung-O-Cohort 2
@en
type
label
A Phase II Trial of Osimertini ...... mor DNA: LiquidLung-O-Cohort 2
@en
prefLabel
A Phase II Trial of Osimertini ...... mor DNA: LiquidLung-O-Cohort 2
@en
P2093
P356
P1476
A Phase II Trial of Osimertini ...... mor DNA: LiquidLung-O-Cohort 2
@en
P2093
Cheol-Kyu Park
Hyun-Ju Cho
Yoo-Duk Choi
Young-Chul Kim
P304
P356
10.4143/CRT.2018.387
P577
2018-09-07T00:00:00Z